Background: Male breast cancer (MBC) is a rare disease compared to female breast cancer (FBC). MBC shares many similarities with FBC, including genetic predisposition factors such as BRCA1/2, CHEK2, PALB2, BRIP1 and RAD51C mutations. However, these alterations can explain only 10% of MBC cases, thus suggesting the contribution of additional susceptibility genes. EMSY has been recently identified as a gene involved in FBC pathogenesis because EMSY can interact with BRCA2 and in this way it is capable of silencing the activation potential of BRCA2. Moreover, breast tumors with amplified EMSY show a phenotypic profile that is similar to BRCA2-related tumors. So, because of the interaction between BRCA2 and EMSY, the latter could play a relevant role in MBC and could explain those MBC cases which pathogenesis can’t be related to BRCA1/BRCA2 mutations. To date, there are no information about the role of EMSY in the pathogenesis of MBC. Taking into account that EMSY has a prognostic value for FBC, studies on its role could have important implications in the elucidation of pathogenetic mechanisms of MBC and in the clinical management of MBC patients. Material and Methods: This study was performed on a series of 100 MBC cases characterized for BRCA1/BRCA2 germ-line mutations and for relevant clinicopathologic features. We have investigated the presence of germ-line mutations and amplification of EMSY by automatic sequencing and qRT-PCR respectively. Statistical analysis was performed using the Fisher exact test. Results: We have found EMSY alterations in 5% of our series. Three of the 37 variants identified (M83K, M1197I and IVS5−1G>A) were shown to be probably damaging by using two prediction softwares. We have found a general amplification percentage of 44% and we have distinguished three different amplification subgroups. A statistically significant association emerged between EMSY amplification and MIB1 (p = 0.03) expression. Conclusions: Our data indicate that alterations of EMSY are involved in MBC pathogenesis at a comparable level as in FBC. New coding variants of this gene seems to be involved in MBC pathogenesis and EMSY amplification allows the identification of distinct subgroups of MBC cases. Moreover, although larger studies are needed, our results suggest that EMSY could be involved not only in MBC pathogenesis but also in tumor progression. Study supported by AIRC (IG 8713).

730 Analysis of EMSY in Italian Male Breast Cancer Patients / Navazio, A. S.; Rizzolo, P.; Silvestri, V.; Graziano, V.; Falchetti, M.; Zanna, I.; Palmirotta, R.; Palli, D.; Ottini, L.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 48:5 suppl.(2012), pp. 173-173. ((Intervento presentato al convegno 22nd Biennial Congress of the European-Association-for-Cancer-Research tenutosi a Barcellona [10.1016/S0959-8049(12)71371-0].

730 Analysis of EMSY in Italian Male Breast Cancer Patients

Navazio, A. S.;Rizzolo, P.;Silvestri, V.;Ottini, L.
2012

Abstract

Background: Male breast cancer (MBC) is a rare disease compared to female breast cancer (FBC). MBC shares many similarities with FBC, including genetic predisposition factors such as BRCA1/2, CHEK2, PALB2, BRIP1 and RAD51C mutations. However, these alterations can explain only 10% of MBC cases, thus suggesting the contribution of additional susceptibility genes. EMSY has been recently identified as a gene involved in FBC pathogenesis because EMSY can interact with BRCA2 and in this way it is capable of silencing the activation potential of BRCA2. Moreover, breast tumors with amplified EMSY show a phenotypic profile that is similar to BRCA2-related tumors. So, because of the interaction between BRCA2 and EMSY, the latter could play a relevant role in MBC and could explain those MBC cases which pathogenesis can’t be related to BRCA1/BRCA2 mutations. To date, there are no information about the role of EMSY in the pathogenesis of MBC. Taking into account that EMSY has a prognostic value for FBC, studies on its role could have important implications in the elucidation of pathogenetic mechanisms of MBC and in the clinical management of MBC patients. Material and Methods: This study was performed on a series of 100 MBC cases characterized for BRCA1/BRCA2 germ-line mutations and for relevant clinicopathologic features. We have investigated the presence of germ-line mutations and amplification of EMSY by automatic sequencing and qRT-PCR respectively. Statistical analysis was performed using the Fisher exact test. Results: We have found EMSY alterations in 5% of our series. Three of the 37 variants identified (M83K, M1197I and IVS5−1G>A) were shown to be probably damaging by using two prediction softwares. We have found a general amplification percentage of 44% and we have distinguished three different amplification subgroups. A statistically significant association emerged between EMSY amplification and MIB1 (p = 0.03) expression. Conclusions: Our data indicate that alterations of EMSY are involved in MBC pathogenesis at a comparable level as in FBC. New coding variants of this gene seems to be involved in MBC pathogenesis and EMSY amplification allows the identification of distinct subgroups of MBC cases. Moreover, although larger studies are needed, our results suggest that EMSY could be involved not only in MBC pathogenesis but also in tumor progression. Study supported by AIRC (IG 8713).
22nd Biennial Congress of the European-Association-for-Cancer-Research
emsy; male breast cancer; brca
04 Pubblicazione in atti di convegno::04c Atto di convegno in rivista
730 Analysis of EMSY in Italian Male Breast Cancer Patients / Navazio, A. S.; Rizzolo, P.; Silvestri, V.; Graziano, V.; Falchetti, M.; Zanna, I.; Palmirotta, R.; Palli, D.; Ottini, L.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 48:5 suppl.(2012), pp. 173-173. ((Intervento presentato al convegno 22nd Biennial Congress of the European-Association-for-Cancer-Research tenutosi a Barcellona [10.1016/S0959-8049(12)71371-0].
File allegati a questo prodotto
File Dimensione Formato  
Navazio_730-Analysis_2012.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 55.65 kB
Formato Adobe PDF
55.65 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1301759
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact